Our competitor Ovid Therapeutics fails a major study of Angelman Syndrome with OV101 ( phase 2 even fragile x):
https://investors.ovidrx.com/news-r...nnounces-phase-3-neptune-clinical-trial-ov101
https://ovidrx.com/science/pipeline/
- Forums
- ASX - By Stock
- OVID FAIL
Our competitor Ovid Therapeutics fails a major study of Angelman...
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$13.75 |
Change
0.000(0.00%) |
Mkt cap ! $1.757B |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 596 | $14.43 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.08 | 177 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 596 | 14.430 |
3 | 617 | 14.420 |
3 | 164 | 13.960 |
1 | 36 | 13.910 |
1 | 488 | 13.870 |
Price($) | Vol. | No. |
---|---|---|
13.080 | 117 | 3 |
13.220 | 378 | 1 |
13.340 | 900 | 10 |
13.360 | 23 | 1 |
13.720 | 18 | 1 |
Last trade - 09.52am 10/09/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
Day chart unavailable